Syntaris Nasal Spray
Flunisolide nasal prep
25mcg/Dose
SYNTEX PHARMACEUTICALS LIMITED
| Pack size | 24ml |
|---|---|
| Dispensing mode | POM |
| Source | UK |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 44.50 AED |
Indications
Syntaris Nasal Spray is used for:
Seasonal Allergic Rhinitis
Adult Dose
Seasonal Allergic Rhinitis
2 sprays each nostril BID; may increase to TID/QID
Child Dose
Seasonal Allergic Rhinitis
<6 years: Safety and efficacy not established
6-14 years: 1 spray each nostril TID, or 2 sprays each nostril BID
Renal Dose
Administration
Prime spray by actuating 5-6 times first before use, if it has not been used for >4 days, or if it has been disassembled for cleaning
Contra Indications
Hypersensitivity
Do not use with untreated local infection involving the nasal mucosa
Recent nasal surgery/injury
Precautions
Replacement of systemic corticosteroids with topical administration can be accompanied by signs of adrenal insufficiency: some patients may experience withdrawal symptoms
Intranasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients Rare reports of nasal septal perforation
Temporary or permanent loss of sense of smell or taste reported
Because of the inhibitory effect of corticosteroids on wound healing, a nasal corticosteroid should be used with caution in patients who have experienced recent nasal septal ulcers, recurrent epistaxis, nasal surgery or trauma, until healing has occurred
Systemic corticoid effects typical of Cushing's syndrome are minimal with recommended doses of topical steroids, this potential increases with excessive doses
Corticosteroids are known to cause immunosuppression resulting in increased susceptibility to infection
Pregnancy-Lactation
Pregnancy
There are no studies in pregnant women to inform a drug-associated risk for birth defects or miscarriage; there are clinical considerations with use in pregnant women to inform a drug-associated risk; in animal reproduction studies, flunisolide administered to pregnant rats and rabbits during of organogenesis produced fetal structural abnormalities; dose in rats and rabbits was approximately 3 and 1 times maximum recommended human daily dose, respectively
Lactation
There is no information on presence of flunisolide in human milk, or effects on breast fed child, or on milk production; because other corticosteroids are excreted in human milk, exercise caution when administering therapy to nursing women
The developmental and health benefits of breastfeeding should be considered along with mother’s clinical need and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition
Interactions
Adverse Effects
Side effects of Flunisolide nasal prep :
>10%
Nasal burning/stinging (13-44%)
Aftertaste (8-17%)
1-10%
Nausea
Epistaxis
Nasal dryness
Pharyngitis
Cough increased
<1%
Hoarseness
Nasal ulceration
Abnormal sense of smell
Sinusitis
Vertical growth suppression
Mechanism of Action
Elicits potent glucocorticoid and weak mineralocorticoid effects; provides direct anti-inflammatory actions to nasal mucosa
Note
Syntaris 25mcg/Dose Nasal Spray manufactured by SYNTEX PHARMACEUTICALS LIMITED. Its generic name is Flunisolide nasal prep. Syntaris is availble in United Arab Emirates.
Farmaco UAE drug index information on Syntaris Nasal Spray is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.